Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 3 |
2023 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
WITHDRAWN: In vitro synergistic activity of cisplatin and EGFR-targeted nanomedicine of anti-Bcl-xL siRNA in a non-small lung cancer cell line model.
Int J Pharm. 2023 Feb 5;632:122335. doi: 10.1016/j.ijpharm.2022.122335. Epub 2022 Oct 22.
Int J Pharm. 2023.
PMID: 36283640
Combination of Nanovectorized siRNA Directed against Survivin with Doxorubicin for Efficient Anti-Cancer Activity in HER2+ Breast Cancer Cells.
Eljack S, Allard-Vannier E, Misericordia Y, Hervé-Aubert K, Aubrey N, Chourpa I, Faggad A, David S.
Eljack S, et al. Among authors: misericordia y.
Pharmaceutics. 2022 Nov 21;14(11):2537. doi: 10.3390/pharmaceutics14112537.
Pharmaceutics. 2022.
PMID: 36432729
Free PMC article.
Item in Clipboard
In vitro synergistic activity of cisplatin and EGFR-targeted nanomedicine of anti-Bcl-xL siRNA in a non-small lung cancer cell line model.
Nguyen PV, Hervé-Aubert K, Lajoie L, Misericordia Y, Chourpa I, David S, Allard-Vannier E.
Nguyen PV, et al. Among authors: misericordia y.
Int J Pharm X. 2022 Nov 13;4:100139. doi: 10.1016/j.ijpx.2022.100139. eCollection 2022 Dec.
Int J Pharm X. 2022.
PMID: 36420371
Free PMC article.
Item in Clipboard
Cite
Cite